SCHEMBL8510193

SCHEMBL8510193

CN1CCC(Oc2ccc(/N=C3/NC(=O)/C(=C/c4c[nH]c5ncccc45)S3)c(Cl)c2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 4/20 0.42
RNASEL Q05823 1/20 0.40
HPGD P15428 1/20 0.39
GSK3B P49841 2/20 0.37
CSNK1E P49674 1/20 0.37
CLK1 P49759 1/20 0.37
CLK2 P49760 1/20 0.37
CLK3 P49761 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK2 Q92630 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
DYRK4 Q9NR20 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
PTPN11 Q06124 1/20 0.37
MAPT P10636 1/20 0.37
RECQL P46063 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CDC7 O00311 3/20 0.37
MMP3 P08254 1/20 0.37
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246304 1.00 DYRK3 (0.42) DYRK3RNASELHPGDGSK3BCSNK1E
SCHEMBL250167 0.96 DYRK3 (0.43) DYRK3RNASELHPGDGSK3BCSNK1E
SCHEMBL250166 0.96 DYRK3 (0.43) DYRK3RNASELHPGDGSK3BCSNK1E
SCHEMBL246096 0.93 CDC7 (0.44) DYRK3HPGDMAPTRECQLNPSR1
SCHEMBL8509684 0.93 CDC7 (0.44) DYRK3HPGDMAPTRECQLNPSR1
SCHEMBL8512920 0.90 SOS1 (0.38) DYRK3HPGDMAPTRECQLNPSR1
SCHEMBL247690 0.90 SOS1 (0.38) DYRK3HPGDMAPTRECQLNPSR1
SCHEMBL8510894 0.89 HPGD (0.38) DYRK3RNASELHPGDGSK3BCSNK1E
SCHEMBL8510897 0.89 HPGD (0.38) DYRK3RNASELHPGDGSK3BCSNK1E
SCHEMBL8513536 0.89 CDC7 (0.45) DYRK3HPGDMAPTRECQLNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120135989-A1 AZAINDOLE DERIVATIVE CRYSTALGENOMICS, INC. (KR) 2012-05-31 US claimed
US-20120135989-A1 AZAINDOLE DERIVATIVE CRYSTALGENOMICS, INC. (KR) 2012-05-31 US disclosed
US-20120135989-A1 AZAINDOLE DERIVATIVE CRYSTALGENOMICS, INC. (KR) 2012-05-31 US disclosed
US-20120135989-A1 AZAINDOLE DERIVATIVE CRYSTALGENOMICS, INC. (KR) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135989-A1 AZAINDOLE DERIVATIVE CDC7, CDCA2, CDC5L DYRK3 1263/4885RNASEL 2872/4885HPGD 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.